MALIGNANT PERITONEAL MESOTHELIOMA -AN UNFORGOTTEN ABDOMINAL MALIGNANCY.

2019 ◽  
pp. 1-2
Author(s):  
A. Mishra ◽  
Ashish Luthra ◽  
C. R. Behera ◽  
Ranjita Panigrahi ◽  
Ranjan Sahoo
Keyword(s):  
Unusual Case ◽  
Asbestos Exposure ◽  
Abdominal Cavity ◽  
Immunohistochemical Analysis ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Tumor Spread ◽  
Tunica Vaginalis Testis ◽  
Abdominal Malignancy ◽  
Rare Malignancy

Malignant peritoneal mesothelioma is a rare lethal malignancy of the serosal membranes of the peritoneum. The pathogenesis and association is strongly related with industrial pollutants asbestos, but less than pleural mesothelioma. Symptoms are nonspecific and related to the tumor spread within the abdominal cavity. CT scan is the investigation of choice and mostly disease is discovered incidentally on routine imaging. Diagnosis is confirmed on histopathology as well as immunohistochemical analysis of markers. The mainstay of treatment is cytoreductive surgery with Hyperthermic intraperitoneal chemotherapy. Here we present a very unusual case of malignant peritoneal mesothelioma diagnosed on routine evaluation of a 62 year old male admitted in emergency for obstructed inguinal hernia. Introduction: Malignant peritoneal Mesothelioma MPM is a very rare malignancy of the abdominal cavity. Mesotheliomas usually originate from the serosal membrane of different body cavities. Pleura is most commonly affected by mesothelioma followed by peritoneum and also other cavities pericardium and tunica vaginalis testis.10 to 30% of all mesothelioma affects peritoneum. Malignant peritoneal mesothelioma is a highly lethal malignant tumor of peritoneum and its pathogenesis is strongly related with industrial pollutant asbestos exposure. Diagnosis is difficult in most of the cases because of its nonspecific presentation and detected on routine abdominal imaging or Surgery

scholarly journals MALIGNANT PERITONEAL MESOTHELIOMA -AN UNFORGOTTEN ABDOMINAL MALIGNANCY

2019 ◽  
pp. 1-2
Author(s):  
A. Mishra ◽  
Ashish Luthra ◽  
C. R. Behera ◽  
Ranjita Panigrahi ◽  
Ranjan Sahoo
Keyword(s):  
Unusual Case ◽  
Asbestos Exposure ◽  
Abdominal Cavity ◽  
Immunohistochemical Analysis ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Tumor Spread ◽  
Tunica Vaginalis Testis ◽  
Abdominal Malignancy ◽  
Rare Malignancy

Malignant peritoneal mesothelioma is a rare lethal malignancy of the serosal membranes of the peritoneum. The pathogenesis and association is strongly related with industrial pollutants asbestos, but less than pleural mesothelioma. Symptoms are nonspecific and related to the tumor spread within the abdominal cavity. CT scan is the investigation of choice and mostly disease is discovered incidentally on routine imaging. Diagnosis is confirmed on histopathology as well as immunohistochemical analysis of markers. The mainstay of treatment is cytoreductive surgery with Hyperthermic intraperitoneal chemotherapy. Here we present a very unusual case of malignant peritoneal mesothelioma diagnosed on routine evaluation of a 62 year old male admitted in emergency for obstructed inguinal hernia. Introduction: Malignant peritoneal Mesothelioma MPM is a very rare malignancy of the abdominal cavity. Mesotheliomas usually originate from the serosal membrane of different body cavities. Pleura is most commonly affected by mesothelioma followed by peritoneum and also other cavities pericardium and tunica vaginalis testis.10 to 30% of all mesothelioma affects peritoneum. Malignant peritoneal mesothelioma is a highly lethal malignant tumor of peritoneum and its pathogenesis is strongly related with industrial pollutant asbestos exposure. Diagnosis is difficult in most of the cases because of its nonspecific presentation and detected on routine abdominal imaging or Surgery

Peritoneal mesothelioma

2016 ◽  
pp. 533-545
Author(s):  
H. Richard Alexander ◽  
Dario Baratti ◽  
Terence C. Chua ◽  
Marcello Deraco ◽  
Raffit Hassan ◽  
...  
Keyword(s):  
Peritoneal Cancer Index ◽  
Abdominal Cavity ◽  
Staging System ◽  
Multimodality Treatment ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Peritoneal Cancer ◽  
Abdominal Disease ◽  
Crs And Hipec ◽  
Rare Malignancy

Malignant peritoneal mesothelioma (MPM) is a rare malignancy arising from the serosa of the abdominal cavity; its natural history is hallmarked by intra-abdominal disease progression. Peritoneal mesothelioma patients generally present with abdominal pain and/or ascites. Pathologically, a positive immunostain for calretinin has markedly increased the accuracy of diagnosis. A new staging system combining extent of tumour burden measured by the peritoneal cancer index (PCI), abdominal nodal status and extra-abdominal metastases has been demonstrated to reliably stratify patient outcomes after cytoreductive surgery (CRS) and hyperthermic perioperative chemotherapy (HIPEC). Over the past decade, the management of these patients has evolved as a multimodality treatment similar to ovarian cancer treatment and now involves CRS and HIPEC.

Peritoneal mesothelioma

2016 ◽  
pp. 533-545
Author(s):  
H. Richard Alexander ◽  
Dario Baratti ◽  
Terence C. Chua ◽  
Marcello Deraco ◽  
Raffit Hassan ◽  
...  
Keyword(s):  
Peritoneal Cancer Index ◽  
Abdominal Cavity ◽  
Staging System ◽  
Multimodality Treatment ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Peritoneal Cancer ◽  
Abdominal Disease ◽  
Crs And Hipec ◽  
Rare Malignancy

Malignant peritoneal mesothelioma (MPM) is a rare malignancy arising from the serosa of the abdominal cavity; its natural history is hallmarked by intra-abdominal disease progression. Peritoneal mesothelioma patients generally present with abdominal pain and/or ascites. Pathologically, a positive immunostain for calretinin has markedly increased the accuracy of diagnosis. A new staging system combining extent of tumour burden measured by the peritoneal cancer index (PCI), abdominal nodal status and extra-abdominal metastases has been demonstrated to reliably stratify patient outcomes after cytoreductive surgery (CRS) and hyperthermic perioperative chemotherapy (HIPEC). Over the past decade, the management of these patients has evolved as a multimodality treatment similar to ovarian cancer treatment and now involves CRS and HIPEC.

scholarly journals Malignant Peritoneal Mesothelioma Interactome with 417 Novel Protein-Protein Interactions

2021 ◽  
Author(s):  
Kalyani B. Karunakaran ◽  
Madhavi K. Ganapathiraju
Keyword(s):  
Gene Expression ◽  
Cell Lines ◽  
Protein Interactions ◽  
Cellular Localization ◽  
Expression Profiles ◽  
Abdominal Cavity ◽  
Peritoneal Mesothelioma ◽  
Pleural Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Protein Protein Interactions

Abstract Malignant peritoneal mesothelioma (MPeM) is an aggressive cancer affecting the peritoneal lining of the abdominal cavity and intra-abdominal organs, with a median survival of ~2.5 years. We constructed an ‘MPeM interactome’ with over 400 computationally predicted protein-protein interactions (PPIs) and over 4,700 known PPIs of 59 literature-curated genes whose activity affects MPeM. Known PPIs of the 59 MPeM-associated genes were derived from BioGRID and HPRD databases. Novel PPIs were predicted by applying the HiPPIP algorithm, which computes features of protein pairs such as cellular localization, molecular function, biological process membership, genomic location of the gene, and gene expression in microarray experiments, and classifies the pairwise features as interacting or non-interacting based on a random forest model. 75.6% of the interactome and 65% of the novel interactors in it were supported by transcriptomic evidence in rodent and human peritoneal mesothelioma/mesothelial cell lines and tumor specimens. 152 drugs targeted 427 proteins in the MPeM interactome. Comparative transcriptome analysis of peritoneal mesothelioma-associated versus drug-induced gene expression profiles revealed 39 repurposable drugs, out of which 29 were effective against peritoneal/pleural mesothelioma and/or peritoneal metastasis/primary peritoneal cancer in clinical trials, animal models or cell lines. Functional modules of chromosomal segregation, transcriptional deregulation, positive regulation of IL-6 production and hematopoiesis were identified from the interactome. Genes with tissue-specific expression in 2 sites of extramedullary hematopoiesis (spleen and thymus) and those correlated with unfavorable prognosis in liver, renal, pancreatic and lung cancers were noted. MPeM interactome showed extensive overlap with the malignant pleural mesothelioma (MPM) interactome and MPM cell line expression profiles. Our findings demonstrate the utility of the MPeM interactome in discovering systems-level functional links among MPeM genes and generating clinically translatable results such as repurposed drugs.

scholarly journals Synchronous multiple primary malignant neoplasms: a case report of malignant peritoneal mesothelioma and neuroendocrine rectal tumor

2021 ◽  
pp. 81-86
Author(s):  
Oleksandr Bondar ◽  
Sergiі Chetverikov ◽  
Viacheslav Maksymovskyi ◽  
Dmytro Atanasov ◽  
Mykhailo Chetverikov ◽  
...  
Keyword(s):  
Minimally Invasive ◽  
Argon Plasma Coagulation ◽  
Asbestos Exposure ◽  
Rectal Tumor ◽  
Peritoneal Mesothelioma ◽  
Special Treatment ◽  
Malignant Neoplasms ◽  
Malignant Peritoneal Mesothelioma ◽  
Invasive Treatment ◽  
Abdominal Tumor

We report a rare case of synchronous malignant peritoneal mesothelioma of the biphasic histological type and neuroendocrine tumor (NET) of the rectum without history of asbestos exposure. During 2 years since manifestation of the disease the patient underwent 3 cytoreductive surgeries (CRS): removal of the tumor of the sigmoid mesentery, resection of the rectosigmoid junction completeness of cytoreduction (CC) 0 (2017), omentectomy and partial parietal peritonectomy CC-0 (2017), atypical resection of S2, S4, S5 liver, the removal of the abdominal tumor with left-sided en-block hemicolectomy, partial parietal peritonectomy, argon-plasma coagulation of tumor foci on the mesentery of the small intestine CC-2 (2018) and Transanal Minimally Invasive Surgery-removal of neuroendocrine rectal tumor (2017). The patient underwent hyperthermic intraperitoneal chemotherapy (HIPEC) twice (during 2nd and 3rd CRS). Different regimens of HIPEC were performed: cisplatin + doxorubicin (2017) and metamycin C (2018). The patient received 4 courses of adjuvant chemotherapy with cisplatin plus pemetrexed in 2017 and 3 courses of the chemotherapy with gemcitabine and carboplatin plus bevacizumab in 2018. The patient survived 21 months after the detection of malignant peritoneal mesothelioma in 2017 and died 4 months after the last cytoreductive surgery from the progression of the disease. Histological subtype of MPMP remains important factor in the prognosis of the disease even on the early stages though patient had received the most aggressive variant of special treatment. Minimally invasive treatment tactics of NET demonstrated clinical effectiveness.  

A single-center retrospective cohort study evaluating the role of neoadjuvant chemotherapy in malignant peritoneal mesothelioma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21093-e21093
Author(s):  
Xiao Wang ◽  
Sharyn I. Katz ◽  
Leonid Roshkovan ◽  
Suzanne Walker ◽  
Sally McNulty ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cohort Study ◽  
Systemic Therapy ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Asbestos Exposure ◽  
Symptom Relief ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Single Center

e21093 Background: Malignant peritoneal mesothelioma (MPM) is a rare variant of malignant mesothelioma, representing < 30% of cases. Standard of care is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) when feasible. The benefit of systemic chemotherapy (chemo) (Neoadjuvant- N, Adjuvant- A, or 1st-line metastatic –M) is not well established and some retrospective studies report worse outcomes with N chemo. However, our institution has favored use of N chemo prior to surgery for symptom relief and surgical optimization. We conducted a single-center retrospective cohort study of MPM patients treated at our institution to evaluate the effect of N vs. A chemo on outcomes. Methods: We identified non-papillary MPM patients via ICD9/10 codes seen at our institution between 1/1/2009 and 9/1/2019. Pts were followed until 1/1/2020. Patients without pathologic diagnosis were excluded. We explored the effect of receipt of CRS, type of systemic therapy, and histology on overall survival. Median overall survival (mOS) from diagnosis was estimated from Kaplan-Meier curves. A Cox proportional hazard model computed hazard ratios (HR) to assess the effect of the exposure on OS. Results: We identified 47 patients with non-papillary MPM: median age 62 years, 77% epithelioid histology, 74.5% white, 55.3% known asbestos exposure. CRS was performed in 24 (51%) and 18/24 (75%) received HIPEC. The majority received systemic therapy (34/47 (72%)). Among those that received chemo and surgery, N chemo was more common than A chemo (N:12 (all platinum/pemetrexed), A:7). Median OS was 52.7 months (mo) overall and 77.2 mo with surgery vs 20.2 mo without (log rank p = 0.006). Toxicity from N chemo did not prevent surgery with 8/12 successfully receiving surgery (1 surgery scheduled, 2 lost to follow up). Of the 10 pts with evaluable scans: 5 had radiographic reduction of disease (2 complete responses by RECIST 1.1), 4 stable disease and 1 with disease growth. N chemo reduced ascites in 3 out of 4 pts with baseline ascites. N chemo was not associated with worse mOS compared to A chemo (HR 0.64, 95% CI 0.1-3.0, p = 0.62). Non-epithelioid histology was not associated with a worse OS compared to epithelioid (HR 1.5, 95% CI 0.6-4.1, p = 0.4). Conclusions: N chemo was not associated with worse outcomes compared to A chemo and toxicity from N chemo did not preclude surgery. In addition, N chemo resulted in reduction of disease burden and ascites in pts with MPM.

An Unusual Case of Malignant Peritoneal Mesothelioma

2009 ◽  
Vol 104 ◽  
pp. S278
Author(s):  
Archana Patel ◽  
Mehul Patel ◽  
Mark Friedman ◽  
Chrisopher Ashley ◽  
Syed Mehdi
Keyword(s):  
Unusual Case ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma

Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features

2013 ◽  
Vol 17 (1) ◽  
pp. 99-103 ◽  
Author(s):  
Yuichi Kinoshita ◽  
Kosho Takasu ◽  
Takashi Yuri ◽  
Katsuhiko Yoshizawa ◽  
Norihisa Uehara ◽  
...  
Keyword(s):  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma

scholarly journals Malignant Peritoneal Mesothelioma Without Asbestos Exposure

2019 ◽  
Vol 12 (1) ◽  
pp. 48-51 ◽  
Author(s):  
Hafsa Abbas ◽  
Julio C Rodriguez ◽  
Hassan Tariq ◽  
Masooma Niazi ◽  
Ahmed Alemam ◽  
...  
Keyword(s):  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma
Sign in / Sign up

Export Citation Format

Share Document